Atypical Antipsychotics in Improvement of Quality of Life in Bipolar Disorder

NCT ID: NCT00745966

Last Updated: 2008-10-06

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 1000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2008-07-31

Brief Summary

The purpose of this study is to reassure the clinical study data on atypical antipsychotics effect on quality of life in Korean Bipolar patients.

Conditions

Naturalistic; Observational

Eligibility Criteria

Inclusion Criteria

• The patient and the patient's legal representative (if any) must understand the nature of the study and must have given written consent.
• Meet DSM-IV-TR criteria for bipolar disorder (bipolar I disorder, bipolar II disorder) at the time of baseline.

Exclusion Criteria

• Serious or unstable, medical illness. Subjects with chronic illness may be included but must be stable and otherwise physically healthy on the basis of a physical examination, medical history.
• Known intolerance for or lack of response to atypical antipsychotics , as judged by the investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

AstraZeneca

Principal Investigators

Joon-Woo Bahn

Role: STUDY_DIRECTOR

Astrazeneca, Korea

Locations

Research Site

Kyunggi-do, Choonchun-si, South Korea

RFesearch Site

Daegu, Joong-gu, South Korea

Countries

South Korea

Other Identifiers

NIS-NKR-SER-2008/1

Identifier Type: -

Identifier Source: org_study_id